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Introduction
Several members of the TNF receptor (TNF-R) super-
family play critical roles in humoral immunity by regu-
lating responses of activated B cells. Stimulation of B cells
through CD40 is necessary for development of germinal
centers, induction of Ig isotype switching, and generation
of B cell memory (1, 2). Similarly, signals received through
CD27 (3), OX40 (4), and TNF-R1 (5) promote human B
cell survival, proliferation, and Ig secretion, while CD40-
induced B cell activation can be antagonized by CD95 (6)
and CD30 (7, 8). Recently, B cell–activating factor belong-
ing to the TNF family (BAFF; also known as BLyS,
TALL-1, zTNF4, THANK, and TNFSF13B) (9–12) has
emerged as an important regulator of B cell homeostasis.
In BAFF-deficient mice, or mice exposed to BAFF-neu-
tralizing agents in vivo, B cell development is severely per-
turbed (13–15). Conversely, BAFF transgenic mice devel-
op autoimmune diseases resembling human systemic
lupus erythematosus (SLE) (16–18) and Sjögren’s syn-
drome (19). Consistent with this has been the finding of
elevated serum levels of BAFF in patients with SLE,
rheumatoid arthritis, and Sjögren’s syndrome (19–21).
The mechanism whereby BAFF exerts these effects is by
improving survival of peripheral B cells (22, 23), which is
thought to allow escape of autoreactive B cells to the
periphery, leading to autoimmune diseases. Taken
together, these findings have led to the proposal that
BAFF plays a critical role in maintaining B cell home-
ostasis, with insufficient signaling by BAFF resulting in
B cell immunodeficiency and excessive signaling causing
B cell–mediated immunopathology (24).
BAFF exerts its effect by binding three known recep-
tors — transmembrane activator of and CAML interac-
tor (TACI), B cell maturation antigen (BCMA), and
BAFF receptor (BAFF-R/BR3) (13, 18, 25–27) — and sub-
sequently eliciting an NF-κB–dependent intracellular
signal transduction pathway (23, 25, 28, 29). TACI has
been reported to be expressed on resting B cells and a
subset of activated T cells (30), while BCMA and BAFF-R
BAFF selectively enhances the survival of plasmablasts
generated from human memory B cells
Danielle T. Avery,1 Susan L. Kalled,2 Julia I. Ellyard,1,3 Christine Ambrose,2
Sarah A. Bixler,2 Marilyn Thien,1,3 Robert Brink,1 Fabienne Mackay,4
Philip D. Hodgkin,5 and Stuart G. Tangye1,3
1Centenary Institute of Cancer Medicine and Cell Biology, Newtown, Australia
2Department of Immunology and Inflammation, Biogen Inc., Cambridge, Massachusetts, USA
3University of Sydney, Sydney, Australia
4Department of Arthritis and Inflammation, Garvan Institute of Medical Research, Darlinghurst, Australia
5Walter & Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria, Australia
The generation of Ig-secreting cells (ISCs) from memory B cells requires interactions between anti-
gen-specific (Ag-specific) B cells, T cells, and dendritic cells. This process must be strictly regulated
to ensure sufficient humoral immunity while avoiding production of pathogenic autoantibodies.
BAFF, a member of the TNF family, is a key regulator of B cell homeostasis. BAFF exerts its effect by
binding to three receptors — transmembrane activator of and CAML interactor (TACI), B cell matu-
ration antigen (BCMA), and BAFF receptor (BAFF-R). To elucidate the contribution of BAFF to the
differentiation of B cells into ISCs, we tracked the fate of human memory B cells stimulated with
BAFF or CD40L. BAFF and CD40L significantly increased the overall number of surviving B cells.
This was achieved via distinct mechanisms. CD40L induced proliferation of nondifferentiated blasts,
while BAFF prevented apoptosis of ISCs without enhancing proliferation. The altered responsive-
ness of activated memory B cells to CD40L and BAFF correlated with changes in surface phenotype
such that expression of CD40 and BAFF-R were reduced on ISCs while BCMA was induced. These
results suggest BAFF may enhance humoral immunity in vivo by promoting survival of ISCs via a
BCMA-dependent mechanism. These findings have wide-ranging implications for the treatment of
human immunodeficiencies as well as autoimmune diseases.
J. Clin. Invest. 112:286–297 (2003). doi:10.1172/JCI200318025.
Received for publication February 3, 2003, and accepted in revised form
May 6, 2003.
Address correspondence to: Stuart Tangye, Centenary Institute
of Cancer Medicine and Cell Biology, Locked Bag Number 6,
Newtown 2042, New South Wales, Australia. 
Phone: 011-61-2-9565-6127; Fax: 011-61-2-9565-6103; 
E-mail: s.tangye@centenary.usyd.edu.au.
Conflict of interest: Susan L. Kalled, Christine Ambrose, and
Sarah A. Bixler are employees of and stockholders in Biogen Inc.
Nonstandard abbreviations used: TNF receptor (TNF-R);
systemic lupus erythematosus (SLE); transmembrane activator of
and CAML interactor (TACI); B cell maturation antigen (BCMA);
BAFF receptor (BAFF-R); antigen (Ag); Ig-secreting cell (ISC);
streptavidin-tricolor (SA-TC); 5-(and 6)-carboxyfluorescein
diacetate succinimidyl ester (CFSE); IgG, IgA, and IgE (IgG/A/E);
IgM and IgD (IgM/D); bone marrow (BM); enzyme-linked
immunosorbent spot (ELISPOT).
expression is restricted to B cells (13, 26, 31). The contri-
butions of interactions between BAFF and these different
receptors to B cell biology appear distinct, however. In
BCMA-null mice, no gross affect on B cell development
or antigen-specific (Ag-specific) immune responses has
been observed (14, 15, 32). In contrast, mature B cells
accumulate in TACI-deficient mice, suggesting TACI may
negatively regulate B cell development (33). Lastly, mice
expressing a naturally mutated form of BAFF-R (the
A/WySnJ strain) exhibit developmental abnormalities in
the B lineage comparable to those found in BAFF-defi-
cient mice (26, 27, 34). This raised the notion that the
BAFF/BAFF-R interaction is primarily responsible for
peripheral B cell survival and development.
While an enormous amount of information regarding
the role of BAFF in the developmental pathway of
murine B cells has been generated, the effect of BAFF on
human B cells and their differentiation remains to be
explored. This is particularly important given the poten-
tial role BAFF has in the development of human autoim-
mune diseases (24). By examining the differentiation of
human splenic B cells in vitro, we found that BAFF
specifically promoted the generation of rapidly-dividing
Ig-secreting cells (ISCs) (plasmablasts) from activated
memory B cells by enhancing their survival. Conse-
quently, large numbers of effector B cells appeared in
cultures containing BAFF. Thus, elevated levels of serum
BAFF may contribute to human autoimmune diseases
not only by breaking tolerance during B cell develop-
ment, but also by enhancing plasmablast survival.
Methods
Reagents. The following Ab’s were used: biotinylated anti-
human IgM, IgD, IgG, IgA, IgE, anti-hamster IgG, phy-
coerythrin-anti-CD27 (PE-anti-CD27), FITC, PE-isotype
control mAb, rabbit polyclonal anti–active caspase-3 anti-
sera (PharMingen, San Diego, California, USA); FITC-
anti-CD20, CD27, and PE-anti-CD19 (Becton Dickinson
Immunocytometry Systems, San Jose, California, USA).
PE- and biotinylated anti-CD38, PE-anti-CD20, biotiny-
lated isotype control mAb, and streptavidin-tricolor
(SA-TC; Caltag Laboratories Inc., Burlingame, California,
USA); PE-anti-Ki67 (DAKO Australia, Botany, Australia);
and PE-conjugated goat polyclonal anti–mouse IgG1
antiserum (Southern Biotechnology Associates, Birm-
ingham, Alabama, USA). Mouse anti-human BAFF-R
(clone 9.1), anti-human TACI (clone C4D7), and hamster
anti-human BCMA (clone C4E2.2) mAb’s were generat-
ed by immunizing with receptor-Fc fusion proteins. Sol-
uble myc-BAFF (26) and anti-TACI mAb were biotinylat-
ed according to established procedures. To produce a
soluble APRIL expression construct, the APRIL gene was
amplified from C57BL/6 genomic DNA and ligated to
form a cDNA sequence encoding amino acids 105–240
and a 5′ XhoI site. This fragment was ligated into a mod-
ified pcDNA3 vector (Invitrogen Corp., Carlsbad, Cali-
fornia, USA) carrying an XhoI site immediately 3′ of an
open reading frame encoding an N-terminal secreto-
ry signal and FLAG tag. The resulting plasmid was
transiently transfected into CHO cells, and supernatant
was collected 3 days later. FLAG-APRIL was purified
using an anti-FLAG-agarose column (Sigma-Aldrich, St.
Louis, Missouri, USA). Purified FLAG-APRIL bound
BCMA and TACI, but not BAFF-R (not shown). Recom-
binant human CD40L was provided by Marilyn Kehry
(Boehringer Ingelheim, Ridgefield, Connecticut, USA).
IL-2 was purchased from Endogen Inc. (Woburn, Massa-
chusetts, USA); IL-10 was provided by Rene de Waal
Malefyt (DNAX Research Institute, Palo Alto, California,
USA); and 5-(and 6)-carboxyfluorescein diacetate succin-
imidyl ester (CFSE) was purchased from Molecular
Probes Inc. (Eugene, Oregon, USA).
Cells. Total human B cells (>98% CD19+) were isolat-
ed from normal spleens as previously described (35,
36). Naive and memory B cells were isolated by sorting
on a FACStar (Becton Dickinson Immunocytometry
Systems) following labeling with FITC-anti-CD20 and
PE-anti-CD27 mAb’s and collecting CD27–CD20+ and
CD27+CD20+ B cells, respectively (37). To isolate IgM-
expressing (nonswitched) and isotype-switched mem-
ory B cells, total B cells were labeled with anti-CD27
mAb and a cocktail of mAb specific for IgG, IgA, and
IgE (IgG/A/E) or IgM and IgD (IgM/D), followed by
SA-TC (38). Bone marrow (BM) aspirates from normal
donors were obtained from the Department of Haema-
tology, Royal Prince Alfred Hospital, Sydney, Australia.
CFSE labeling and B cell cultures. To investigate cell sur-
vival, B cells were cultured in media alone or in the pres-
ence of BAFF (2.5 µg/ml) or CD40L (1:250 dilution of
the membrane preparation). At different times, a known
number of CaliBRITE beads (Becton Dickinson
Immunocytometry Systems) were added to culture wells
prior to harvesting, and the number of viable B cells were
calculated as a function of the ratio of beads to live cells
(39). To examine the effect of BAFF on B cell differenti-
ation, memory B cells were labeled with CFSE (39) and
cultured in 48-well plates (4 × 105/ml; Becton Dickinson
Labware, Franklin Lakes, New Jersey, USA) for 4 days
with CD40L, IL-2 (50 U/ml), and IL-10 (100 U/ml). The
cells were harvested, washed, and recultured (approxi-
mately 2 × 105/ml) with or without IL-2/IL-10 in the
absence or presence of CD40L or BAFF (2.5 µg/ml) for
an additional 4 days (36, 40). Primary plasma cells were
purified from spleen and BM by sorting CD38++CD20+/–
cells (41) and then cultured (approximately 5 × 103/well)
in round-bottomed 96-well plates for 4–5 days. All cul-
tures were performed as described previously (36).
Immunofluorescent staining. For phenotypic analysis, cells
were incubated on ice with specific or the appropriate iso-
type control mAb and analyzed on a FACScalibur using
CellQuest software (Becton Dickinson Immunocytome-
try Systems). To determine expression of BAFF-Rs on dif-
ferent B cell populations, splenic B cells or BM mononu-
clear cells were incubated with either mouse anti–human
BAFF-R mAb followed by PE-goat anti-mouse IgG1-PE
Ab, hamster anti–human BCMA mAb followed by
biotinylated anti–hamster Ig mAb, biotinylated BAFF or
biotinylated anti–human TACI mAb, and then SA-TC.
The Journal of Clinical Investigation | July 2003 | Volume 112 | Number 2 287
Unoccupied binding sites of the secondary Ab were
blocked with mouse IgG1, and the cells were incubated
with FITC- or PE-anti-CD27 mAb, FITC-anti-CD20
mAb, or PE- or biotinylated anti-CD38 mAb followed by
SA-TC. Binding of BAFF to and expression of BAFF-R,
BCMA, and TACI on different B cell populations were
determined by gating on CD27– (naive) or CD27+ (mem-
ory) B cells (37), or CD38– or CD38+ B cells present in in
vitro cultures (36, 38, 40). Expression of Ki67 and active
caspase-3 were used to assess cell proliferation (2) and
apoptosis (42), respectively, as described previously (36).
To assess expression of caspase-3, cells present in both the
live and dead populations, defined by scatter plots, were
analyzed. According to the manufacturer, the anti–active
caspase-3 Ab detects the same frequency of apoptotic cells
as the annexin V binding assay (Pharmingen).
Analysis of Ig secretion. Secretion of IgM, IgG, and IgA
was performed using Ig heavy chain–specific ELISA
and enzyme-linked immunosorbent spot (ELISPOT)
assays as described previously (36).
Statistical analysis. Data were analyzed by ANOVA
using Prism software (GraphPad Software for Science
Inc., San Diego, California, USA).
Results
Expression of BAFF-Rs on human B cells. Human splenic B
cells bound soluble BAFF (Figure 1a). An assessment of
expression of the currently identified BAFF-Rs —
BAFF-R, TACI, and BCMA — revealed BAFF-R was
highly expressed on human splenic B cells (Figure 1b),
while neither TACI (Figure 1c) nor BCMA (Figure 1d)
were detected. The specificity of the anti-BCMA and
anti-TACI mAb’s was confirmed by staining 293T cells
transiently transfected with plasmids containing the
appropriate cDNA (Figure 1, e and f). Thus, the pre-
dominant BAFF-binding protein expressed by freshly
isolated human B cells is BAFF-R.
BAFF promotes survival of human memory B cells but does
not induce proliferation. BAFF can prevent apoptosis of
murine B cells (22, 23). To extend these studies, human
splenic B cells were cultured for 4 days in media alone
or with recombinant human BAFF. Under these con-
ditions, BAFF increased cell viability twofold to three-
fold, as defined by cell recovery at the end of the culture
period, compared with unstimulated cultures (Figure
2, a and b). When the effect of BAFF on B cell subsets
defined by differential expression of CD27 (37) was
examined, BAFF consistently promoted survival of
memory cells (2.0- ± 0.15-fold increase in cell recovery
over unstimulated cultures; mean ± SD, n = 3), while its
effect on naive B cells was variable (1.4- ± 0.4-fold
increase; Figure 2b). In contrast, CD40L, a well-known
survival factor for human B cells (1, 2), equally
enhanced survival of naive and memory B cells (10.7-
and 7.4-fold increase, respectively, n = 3; Figure 2b).
The effect of BAFF on proliferation was examined by
culturing CFSE-labeled memory B cells for 5 days and
then determining the proportion of divided cells (39).
Approximately 95% of unstimulated memory B cells
remained undivided during this period (i.e., division 0;
Figure 2c). In the presence of CD40L, approximately 40%
of harvested memory B cells were detected in divisions
1–5 (Figure 2c). In contrast, the distribution of memory
B cells across divisions in BAFF-treated cultures was sim-
ilar to that in unstimulated cultures, demonstrating that
although BAFF enhanced survival of memory B cells, it
did not induce their proliferation (Figure 2c).
BAFF increases recovery of human memory B cells preactivat-
ed with CD40L and IL-2/IL-10. The ability of some factors
to influence B cell responses changes with the activation
state of the cells. For instance, resting human B cells
respond poorly to stimulation with anti-Ig and IL-4; how-
ever, activation with anti-Ig Ab prior to exposure to IL-4
resulted in robust proliferation (43). Similarly, IL-10 can
either enhance viability or induce apoptosis of human B
cells depending on the time at which activated B cells
were exposed to IL-10 (44). Furthermore, although liga-
tion of CD27 by CD70 has minimal effect on prolifera-
tion of resting B cells (8), culturing activated B cells with
CD70-expressing transfectants increased Ig production
and the generation of CD38+ plasmablasts in vitro (3).
For these reasons, the effect of BAFF on survival of mem-
ory B cells preactivated in vitro was examined.
Purified memory cells were first induced to proliferate
and differentiate with CD40L and IL-2/IL-10 (40) for 4
days before being washed and recultured for a further 4
days under varying conditions (Figure 3a). These sec-
ondary cultures compared the effect of CD40L or BAFF
to cultures containing medium only or IL-2/IL-10 (Fig-
ure 3a). More than 75% of B cell blasts died during sec-
ondary culture when exposed to media alone, while eight-
fold more cells were recovered if CD40L was included
(Figure 3b). Similarly, BAFF increased cell recovery,
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Figure 1
Expression of BAFF-Rs on human B cells. Human splenic B cells were
incubated with (a) soluble BAFF or mAb specific for (b) BAFF-R, (c)
TACI, or (d) BCMA. These results represent experiments performed
using B cells from three to five different donor spleens. (e and f) 293T
cells were transiently transfected with cDNA encoding human (e)
BCMA or (f) TACI. Expression of the transfected protein was assessed
using the anti-BCMA and anti-TACI mAb’s described in c and d. For
each plot, the thick and thin lines represent the fluorescence of cells
incubated with the specific or control reagent, respectively.
though to a lesser extent than CD40L (Figure 3b). The
inclusion of IL-2/IL-10 in secondary culture also
enhanced recovery of cells (compare Figures 3, b and e),
with the level further increased by CD40L or BAFF (Fig-
ure 3e) such that approximately similar numbers of B
cells were recovered from these cultures. Thus, although
BAFF only had a small effect on survival of resting mem-
ory B cells (see Figure 2), its effect was more prominent
on preactivated cells where its ability to increase the recov-
ery of cultured B cells approximated that of CD40L.
BAFF preferentially promotes survival of differentiated CD38+
B cells. When human memory B cells are cultured with
CD40L and IL-2/IL-10, a population of CD38+ B cells is
generated whose proliferation and survival, in contrast to
the CD38– population, becomes independent of further
stimulation from CD40L (36). This CD38+ population
includes rapidly dividing ISCs (36, 38) that resemble
plasmablasts (45), while the CD38– population contains
some ISCs but predominantly nondifferentiated B blasts
(36, 38). It was therefore of interest to compare the effect
of CD40L and BAFF on the generation of these popula-
tions of differentiated B cells. The proportion of CD38+
B cells present in the total B cell population recovered
from secondary cultures containing BAFF or CD40L
showed a marked difference, with a greater percentage
being found in the presence of BAFF (Figure 3, c and f).
This effect was specific for BAFF because it was abrogat-
ed when cultures were performed in the presence of sol-
uble TACI-Ig. Notably, although the overall number of B
cells in cultures containing only CD40L exceeded that
containing BAFF alone twofold (Figure 3b), a similar
number of CD38+ cells was generated in both of these
cultures, and this number exceeded that in unstimulated
cultures fivefold (Figure 3d). In cultures containing 
IL-2/IL-10, 30-fold more CD38+ B cells were generated
than in cultures performed in medium alone (compare
Figures 3, d and g). Strikingly, the number of CD38+ B
cells was significantly increased (fourfold) in the presence
of BAFF compared with IL-2/IL-10 alone (Figure 3g). In
contrast to its effect on CD38+ B cells, BAFF had no sig-
nificant impact on the number of CD38– B cells present
in the secondary cultures, irrespective of whether IL-2/
IL-10 were present or not, while CD40L significantly
increased the number of these cells fivefold to tenfold
independently of the cytokines (Figure 3, d and g). Thus,
in the presence of IL-2/IL-10, CD40L and BAFF appear
to have distinct roles in expanding or maintaining CD38–
and CD38+ B cells, respectively.
BAFF and CD40L specifically affect the behavior of differ-
ent populations of activated B cells. In an earlier study, we
reported that the generation of CD38+ B cells from
activated memory B cells increased in frequency with
successive cell divisions (36). The distinct roles of
CD40L and BAFF in promoting the persistence of
CD38– and CD38+ B cells, respectively, may have been
due to a combination of effects on survival, prolifera-
tion, or differentiation rate per division. We first exam-
ined this in more detail by following the fate of cells
with different division histories using CFSE (39). Con-
tour plots of CFSE profiles (showing division) versus
CD38 expression of cells recultured with IL-2/IL-10
alone (Figure 4a) or in the presence of CD40L (Figure
4b) or BAFF (Figure 4c), revealed three populations:
CD38– B cells in early divisions (population 1), CD38–
B cells in late divisions (population 2), and CD38+ B
cells also present in later divisions (population 3; Fig-
ure 4). The distribution of these populations, howev-
er, differed greatly depending on the activators present
in the secondary culture. Specifically, in the presence
of IL-2/IL-10, the greatest proportion of cells were
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Figure 2
BAFF enhances survival but does not affect proliferation of human B cells. (a) Total splenic B cells were cultured in medium alone (squares)
or with BAFF (circles; 2.5 µg/ml) and the number of viable cells determined after 2 and 4 days. (b) Total, naive, or memory B cells were cul-
tured with media alone (black bars), BAFF (white bars), or CD40L (gray bars), and the number of surviving cells was quantitated after 4
days. Each point represents the mean ± SD of duplicate samples and is representative of three different experiments. Error bars are shown
for all graphs; however, they are not always visible. For the experiment shown, BAFF increased the survival of total, naive, and memory B cells
1.95-, 1.4-, and 2.1-fold, respectively, while CD40L increased survival 9.2-, 9.7-, and 6.3-fold. (c) CFSE-labeled memory B cells were cul-
tured for 5 days with media alone (squares), CD40L (diamonds), or BAFF (circles). The percentage of cells in each division was determined
by division slicing. These results are representative of three different experiments.
CD38+ (population 3), while population 2 was least
represented (Figure 4a). In contrast, CD38– B cells
present in later divisions (population 2) dominated
cultures containing CD40L and IL-2/IL-10 (Figure
4b). Supplementing cultures with BAFF and IL-2/IL-10
significantly increased population 3 at the expense of
population 1, yet had little effect on the relative pro-
portion of population 2 (Figure 4c). Assessment of
absolute numbers, rather than proportions, of cells
clearly revealed that CD40L and IL-2/IL-10 potently
expanded population 2 B cells (13-fold more com-
pared with cytokines alone), while the greatest effect
of BAFF was to increase the number of population 3
(CD38+) B cells (Figure 4d). Thus, CD40L maintains
the pool of CD38– B blasts, while BAFF favors genera-
tion of the CD38+ population, which contains ISCs.
Proliferative and antiapoptotic
effects of CD40L and BAFF on CD38+
and CD38– B cells. The results
described above raised the ques-
tion of the mechanisms responsi-
ble for the differential effects of
BAFF and CD40L on CD38+ and
CD38– B cells. To answer this, the
division history of these popula-
tions during primary culture with
CD40L and IL-2/IL-10 was com-
pared with that of cells recovered
from the different secondary cul-
tures. After 4 days of primary cul-
ture with CD40L and IL-2/IL-10,
only approximately 10% of CD38–
B cells present remained undivid-
ed while the remainder were dis-
tributed across divisions 1–6 (Fig-
ure 5a; bold line). Following
secondary culture with IL-2/IL-10
alone or with BAFF, the division
profile of CD38– B cells was simi-
lar to that of cells following pri-
mary culture (Figure 5a). In the
presence of CD40L and IL-2/IL-10,
however, CD38– B cells continued
to proliferate as indicated by a
marked reduction in the propor-
tion of undivided cells, with the
majority of them residing in divi-
sion 5 (Figure 5a).
When the division history of
CD38+ B cells was examined after
primary culture, cells were detect-
ed in divisions 3–7 (Figure 5b,
bold line). In contrast to CD38– B
cells, CD38+ B cells exhibited a
proliferative burst on reculture
with IL-2/IL-10, which was unaf-
fected by the addition of CD40L
or BAFF (Figure 5b). This sug-
gested BAFF may increase the
recovery of CD38+ B cells by improving cell survival. To
investigate this possibility, the proportion of apoptot-
ic cells was quantitated by determining expression of
active caspase-3 (42) in populations 2 and 3 using an
anti–active caspase-3–specific mAb. To demonstrate
the specificity of this reagent, the human B cell line
Ramos was cultured overnight in the absence of serum
to induce apoptosis, after which expression of active
caspase-3 was determined by intracellular staining.
Analyzing all cells revealed that 40% expressed active
caspase-3 (Figure 5c, thin line). The frequency of active
caspase-3+ cells was reduced to less than 2% and
increased to more than 95% when only cells present in
the live and dead cell gates, respectively, as assessed by
light-scatter characteristics, were analyzed (Figure 5c;
live, dotted line; dead, bold line). Based on this result,
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Figure 3
BAFF promotes the generation of CD38+ B cells from activated memory B cells. (a) The
scheme of the two-step culture system used. CFSE-labeled memory B cells were initially cul-
tured with CD40L and IL-2/IL-10 for 4 days, harvested, washed, and then recultured with
media (b–d) or IL-2/IL-10 (e–g) alone (black bars) or in the presence of CD40L (white bars)
or BAFF (gray bars). After an additional 4 days, the total number of cells (b and e) and per-
centage of CD38+ B cells (c and f) in each culture were determined. The number of CD38–
and CD38+ B cells (d and g) was calculated by multiplying total cell number by the frequen-
cy of CD38– and CD38+ cells, respectively. The values represent the mean ± SEM of four (b–d)
or five (e–g) experiments. The horizontal lines in b and e indicate the mean number of B cells
present at the beginning of the secondary culture.*P < 0.05; **P < 0.01; ***P < 0.001.
all B cells present in the secondary culture (i.e., live and
dead) were included in the analysis. In the presence of
IL-2/IL-10, more than 80% of all population 2 and
approximately 70% of population 3 (CD38+) B cells
expressed active caspase-3 (Figure 5d). CD40L signifi-
cantly reduced the level of apoptosis in CD38– B cells
to less than 35%; it also increased survival of CD38+ B
cells, although this varied for cells in different experi-
ments (Figure 5d). By contrast, BAFF significantly
improved survival of CD38+ B cells, but exerted only a
modest effect on CD38– B cells (Figure 5d). Taken
together, these data suggest BAFF is a survival factor
for CD38+ B cells only, while CD40L increases survival
of CD38–, and occasionally CD38+, B cells.
BAFF increases the generation of ISCs. The above experi-
ments revealed BAFF preferentially enhanced survival
of CD38+ plasmablasts generated in vitro. The next
step was to determine whether the enhancing effect of
BAFF on survival of CD38+ B cells led to increased Ig
secretion. Reculture with media alone resulted in pro-
duction of IgM, IgG, and IgA (Figure 6a), the levels of
which could be increased five- to tenfold by IL-2/IL-10
(Figure 6b). Addition of BAFF increased Ig production
by B cells recultured in the absence and presence of 
IL-2/IL-10, as did CD40L (Figure 6, a and b). BAFF was
shown to cause significant increases in IgM and IgA
production compared with secondary cultures per-
formed with media or IL-2/IL-10 alone, whereas
CD40L significantly increased production of IgA in
media-only cultures and IgM in IL-2/IL-10 cultures. In
contrast, neither of them led to a significant increase in
IgG secretion. This effect on Ig production was specif-
ic for BAFF because the amount of IgA produced in sec-
ondary cultures containing BAFF and IL-2/IL-10 was
reduced in the presence of soluble TACI-Ig to levels
observed in cultures containing IL-2/IL-10 only, while
IgA production induced by IL-2/IL-10, with or without
CD40L, was unaffected (Figure 6c).
It was next determined whether the increased pro-
duction of Ig observed in the presence of BAFF reflect-
ed an increase in the number of ISCs or an increase in
the amount of Ig produced per cell. For these experi-
ments, preactivated memory B cells were recultured
with IL-2/IL-10 alone or in the presence of BAFF for an
additional 3 days. ELISPOT assays were then performed
on the whole population of viable cells. The proportion
of ISCs was increased from 32.8% in the presence of 
IL-2/IL-10 to 45.4% in the presence of BAFF and IL-2/
IL-10. Importantly, the absolute number of ISCs in sec-
ondary cultures containing BAFF and IL-2/IL-10 was
increased more than twofold compared with cultures
containing only the cytokines (Figure 6d). The most
striking effect of BAFF was on the generation of IgA
ISCs. In the two experiments performed, BAFF in com-
bination with IL-2/IL-10 increased IgA-secreting cells
7.3- and 4.4-fold compared with IL-2/IL-10 alone, while
its effect on cells secreting the other Ig isotypes was
approximately twofold (Figure 6d). Thus, the increased
Ig production occurring in the presence of BAFF results
from an increase in the number of effector ISCs, rather
than an increased rate of production of Ig by ISCs.
Elevated levels of IgA in secondary cultures containing
BAFF could have resulted from expansion of IgA-express-
ing B cells present in the memory population or induc-
tion of Ig isotype switching by nonswitched IgM/D+
memory B cells, which comprise a significant population
of the total splenic memory B cell population (35, 38). To
examine this, switched and nonswitched memory B cells
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Figure 4
Differential effect of CD40L and BAFF on the gen-
eration and maintenance of populations of acti-
vated memory B cells. CFSE-labeled memory B
cells were cultured with CD40L and IL-2/IL-10 for
4 days, washed, and then recultured for an addi-
tional 4 days with (a) IL-2/IL-10, (b) CD40L and
IL-2/IL-10, or (c) BAFF and IL-2/IL-10. After the
secondary culture, cell populations defined by
CFSE dilution and CD38 expression were deter-
mined. Population (popn.) 1: undivided early divi-
sions/CD38–; population 2: late divisions/CD38–;
population 3: late divisions/CD38+. The values
represent the mean percentage of cells (± SEM of
seven independent experiments) comprising pop-
ulations 1, 2, and 3. (d) The absolute number of
cells present in populations 1 (black bars), 2
(white bars), and 3 (gray bars) in secondary cul-
tures containing IL-2/IL-10, CD40L and IL-2/
IL-10, or BAFF and IL-2/IL-10 was determined by
multiplying the total cell number by the frequen-
cy of cells, using the gates illustrated in a–c. Each
value represents the mean ± SEM of five inde-
pendent experiments.
were isolated and then cultured according to the scheme
illustrated in Figure 3a. Reculture with IL-2/IL-10 alone
resulted in production of low but detectable amounts of
IgA from IgM-expressing memory B cells (Figure 6e),
while substantially more IgA was produced by switched
IgG/A/E+ memory B cells (Figure 6f). Addition of CD40L
caused an approximately twofold increase in IgA pro-
duction by both populations of B cells (Figure 6, e and f).
BAFF led to a much greater increase in IgA production by
switched memory B cells (Figure 6f), however. Thus, the
majority of IgA secreted by total memory B cells in
response to BAFF stimulation is likely to be derived from
isotype-switched memory B cells.
Our previous studies demonstrated that ISCs were
present in both the CD38– and CD38+ populations of
divided B cells (populations 2 and 3; ref. 36). Thus, the
effect of BAFF on Ig secretion by these different subsets
was examined by sort-purifying B cells corresponding
to populations 2 and 3 and reculturing them for an
additional 2 days with IL-2/IL-10 in the absence or
presence of CD40L or BAFF. Although the amount of
IgA produced by CD38– B cells was unaffected by either
CD40L or BAFF (Figure 6g), secretion by CD38+ B cells
was consistently augmented by BAFF (1.53-fold ± 0.07-
fold increase, n = 3; Figure 6g). The differential sensi-
tivity of CD38– and CD38+ ISCs to BAFF resulted in
secretion of up to four times more IgA by CD38+ B cells
compared with CD38– B cells (Figure 6g). Thus,
although CD38– and CD38+ B cells both produced IgA,
BAFF appeared to specifically enhance the function of
ISCs within the CD38+ population.
Activated B cells alter expression of BAFF-Rs during differ-
entiation to CD38+ B cells. Expression of BAFF-R, TACI,
and BCMA by activated B cells was investigated next to
determine whether the selective sensitivity of CD38– and
CD38+ B cells to BAFF resulted from differential expres-
sion of the various BAFF-Rs. Due to the disparate sen-
sitivity to CD40L exhibited by these cells for their con-
tinued expansion and survival (Figure 5), expression of
CD40 was also determined. For this analysis, cultures of
activated B cells were divided into populations 1, 2, and
3 (see Figure 4). BAFF was shown to bind all three pop-
ulations, although binding to population 3 was
reduced relative to populations 1 and 2 (Figure 7a). The
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Figure 5
CD40L and BAFF have distinct effects on proliferation and survival of CD38– and CD38+ B cells. CFSE-labeled memory B cells were cultured
as described in Figure 3a. The percentage of (a) CD38– and (b) CD38+ B cells present in different divisions after primary culture (day 4; thick
line, squares) or following secondary culture with IL-2/IL-10 (diamonds), CD40L and IL-2/IL-10 (circles), or BAFF and IL-2/IL-10 (triangles)
was determined by division slicing. Each value represents the mean ± SEM of five different experiments. (c) Ramos B cells were cultured
overnight in the absence of serum. Expression of active caspase-3 by total cells (thin line), live cells (dotted line), and dead cells (bold line)
was then determined by intracellular staining and flow cytometry using gates established according to forward- and side-scatter character-
istics. (d) The percentage of populations 2 and 3 B cells expressing active caspase-3 following secondary culture with IL-2/IL-10 (black bars),
CD40L and IL-2/IL-10 (white bars), or BAFF and IL-2/IL-10 (gray bars) was determined as described for c by gating on both live and dead
cells. Each value represents the mean ± SEM of three different experiments. **P < 0.01.
phenotype of undivided CD38– B cells (population 1)
was similar to freshly isolated memory B cells (see Fig-
ure 1), with these cells expressing BAFF-R and CD40,
but not TACI or BCMA (Figure 7, left panel). Popula-
tion 2 B cells were heterogeneous for expression of
BAFF-R and CD40, with some cells downregulating
expression of both receptors, while TACI remained very
low and BCMA weak but detectable (Figure 7, middle
panel). By contrast, the majority of CD38+ B cells (pop-
ulation 3) lost expression of BAFF-R, while the levels of
CD40 were uniformly reduced more than tenfold com-
pared with population 1 (Figure 7, right panel). Impor-
tantly, expression of BCMA was further increased com-
pared with population 2 (Figure 7d, right panel). Thus,
although CD38+ B cells retain the ability to bind BAFF
(Figure 7a), the receptors responsible for this interaction
appear to differ from those used by resting memory B
cells. It is therefore possible that the effect of BAFF on
CD38+ B cells is mediated through the acquired expres-
sion of BCMA as well as residual expression of BAFF-R.
APRIL, a homologue of BAFF, also promotes survival of
human ISCs. The amino acid sequence of BAFF exhibits
greatest homology with APRIL (9, 24). These two ligands
both bind TACI and BCMA with similar affinities; how-
ever, only BAFF binds BAFF-R (15, 24, 26). We hypothe-
sized that if BAFF increased survival of CD38+ ISCs by
interacting with BCMA, this effect would be duplicated
by APRIL. In contrast, if this effect resulted from BAFF
binding residual BAFF-R on CD38+ B cells (Figure 7b),
APRIL would not substitute for BAFF. This was exam-
ined by performing secondary cultures in the presence
of IL-2/IL-10 alone or with CD40L, BAFF, or mouse
APRIL (which can also bind human BCMA; refs. 15, 26).
Compared with IL-2/IL-10 alone, both BAFF and APRIL
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Figure 6
BAFF increases the generation of ISC from activated memory B cells. (a and b) Memory B cells were preactivated with CD40L and IL-2/IL-10
for 4 days and then recultured with (a) media (black bars), or (b) IL-2/IL-10 alone (black bars) or in the presence of CD40L (white bars) or
BAFF (gray bars). Each value represents the mean Ig secretion ± SEM of five (a) or seven (b) experiments using cells from different donors.
*P < 0.05; **P < 0.01. (c) Secondary B cell cultures were performed in the absence (white bars) or presence (black bars) of soluble TACI-Ig
(20 µg/ml). The values represent the mean IgA ± SD of duplicate samples. (d) Memory B cells were preactivated with CD40L/IL-2/IL-10 for 4
days and then recultured with IL-2/IL-10 alone or in the presence of BAFF. The total number of cells secreting IgM (black bars), IgG (white
bars), and IgA (gray bars) was determined by ELISPOT. Expt, experiment. (e) IgM+ and (f) IgG/A/E+ memory B cells were isolated by cell sort-
ing, and the amount of IgA secreted during secondary culture with IL-2/IL-10 (black bars), CD40L/IL-2/IL-10 (white bars), or BAFF/IL-2/IL-10
(gray bars) was determined. The scales of the y axes of these graphs are different to enable meaningful comparison. (g) Cells corresponding
to populations 2 and 3 were isolated by sorting, recultured with IL-2/IL-10 (black bars), CD40L/IL-2/IL-10 (white bars), or BAFF/IL-2/IL-10
(gray bars), and the amount of IgA secreted was then determined.
increased the number of CD38+ B cells and secretion of
IgA by threefold (Figure 8, a and b), as well as the pro-
portion of CD38+ B cells (population 3) by 25–40%. These
data therefore suggest BCMA induced on CD38+ B cells
is functional and is responsible for mediating BAFF-
induced survival of ISCs rather than residual BAFF-R.
Function of BAFF-Rs on in vivo–generated ISCs. The abil-
ity of BAFF to increase Ig secretion by CD38+ B cells
generated in vitro suggested it may have a similar role
on primary plasma cells. The high rate of proliferation
of in vitro–generated CD38+ B cells indicated these cells
resembled plasmablasts, however, rather than termi-
nally differentiated nondividing plasma cells (Figure 5)
(36, 38). To identify the developmental stage at which
BAFF may act to increase Ig secretion in vivo, primary
CD38++CD20+/– cells at distinct stages of differentia-
tion were used (Table 1). In experiment 1, the splenic
CD38++CD20+/– population contained predominantly
plasmablasts, as revealed by expression of the prolifer-
ation-associated antigen Ki67 by more than 90% of
these cells, while the same subset of cells derived from
another spleen (experiment 2) or BM (experiment 3)
was more akin to terminally differentiated plasma cells
(<1% Ki67+, Table 1). Total CD38++CD20+/– cells secret-
ed detectable amounts of IgM, IgG, and IgA in the pres-
ence of IL-2/IL-10 (Table 1). Following addition of
BAFF to plasmablasts, Ig secretion was increased
approximately twofold, compared with cultures con-
taining cytokines alone (Table 1, experiment 1). BAFF
exerted relatively little effect on Ig secretion by fully dif-
ferentiated plasma cells (Table 1, experiments 2 and 3),
however. Interestingly, plasmablasts tested in experi-
ment 1 exhibited higher levels of expression of BCMA
than plasma cells from the other donors, while expres-
sion of BAFF-R on all CD38++CD20+/– B cells was extin-
guished (data not shown). Thus, the data derived from
examining Ig secretion by in vitro–generated and in
vivo–derived CD38++CD20+/– B cells suggest the effect
of BAFF is restricted to plasmablasts, which retain the
capacity to divide, rather than terminally differentiat-
ed nondividing plasma cells.
Discussion
BAFF has emerged as a major regulator of murine B cell
homeostasis (24). Our results extend the knowledge of
BAFF not only to its functions in the later stages of B cell
differentiation, but also to humans. BAFF was found to
improve survival of human memory B cells in vitro with-
out inducing cell division, consistent with its antiapop-
totic and nonmitogenic effects reported previously for
murine B cells (22, 23). The ability of BAFF to increase
survival was particularly apparent in cultures of memory
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Figure 8
APRIL and BAFF are equally efficient at increasing survival of human
ISCs. Memory B cells were cultured with CD40L and IL-2/IL-10 for 4
days, washed, and then recultured for an additional 4 days with IL-2/
IL-10 alone (black bars) or in the presence of CD40L (white bars),
BAFF (dark gray bars), or APRIL (light gray bars; 500 ng/ml). The (a)
number of CD38+ B cells and (b) secretion of IgA was then deter-
mined. Each value represents the mean ± SD of duplicate samples.
Figure 7
Altered expression of BAFF-Rs and CD40L on activated human B cells.
CFSE-labeled memory B cells were cultured as in Figure 3a. Cells were
harvested and incubated with anti-CD38 mAb in combination with (a)
soluble BAFF or mAb specific for (b) BAFF-R, (c) TACI, (d) BCMA, or
(e) CD40. Expression of these receptors on B cells in populations 1 (left
panel), 2 (middle panel), and 3 (right panel) was determined. For each
plot, the thick and thin lines represent the fluorescence of cells incu-
bated with the specific or isotype control mAb or protein, respective-
ly. These results are representative of three independent experiments.
B cells preactivated with the T cell–derived stimuli
CD40L and IL-2/IL-10. In fact, similar numbers of viable
cells were recovered from secondary cultures established
with IL-2/IL-10 and either CD40L or BAFF. CD40L and
BAFF, however, appeared to target different populations
of cells through different mechanisms. BAFF specifical-
ly enhanced survival of differentiated CD38+ ISCs by
inhibiting apoptosis, while CD40L increased the num-
ber of CD38– blasts by promoting further proliferation
and reducing apoptosis. The level of Bcl-2 expressed by
CD38+ B cells generated in the presence of BAFF and 
IL-2/IL-10 was similar to CD38+ B cells from cultures
containing IL-2/IL-10 with or without CD40L (data not
shown). Thus, although upregulation of Bcl-2 has been
implicated in the antiapoptotic effect of BAFF on
murine B cells (16, 46), BAFF may mediate its viability-
enhancing effect on human CD38+ B cells by modulat-
ing expression of pro- and antiapoptotic genes other
than Bcl-2, such as Bcl-x, A1 (23), or Blk (47).
BAFF also increased the levels of IgM and IgA, but
not IgG, by increasing the number of ISCs generated.
This is remarkably consistent with the findings that
mice either transgenic for BAFF or injected with BAFF
contained significantly increased levels of serum IgM
and IgA, but not IgG (10, 17, 23), confirming the valid-
ity of our in vitro system for examining B cell differen-
tiation. Furthermore, these in vivo and in vitro obser-
vations point to the existence of a novel factor that can
augment production of IgG by activated mouse and
human B cells. The effect of BAFF on human B cells
appeared to be mediated by directly stimulating CD38+
ISCs derived from isotype-switched memory cells,
rather than inducing Ig isotype switching by IgM+
memory B cells, as recently proposed for naive B cells
(48). Thus, BAFF may be involved in mucosal immune
responses characterized by production of high levels of
IgA and IgM. Furthermore, the exaggerated humoral
immune responses observed in mice administered
BAFF may result from specific enhancement of plas-
mablast survival in vivo (10, 23). Consequently, BAFF
may be a therapeutic candidate for treating patients
with IgA deficiency in whom B cells are present but fail
to secrete IgA (49, 50). Since this defect can be partial-
ly overcome in vitro by IL-10 (49), it is possible that
BAFF and IL-10 might completely restore IgA produc-
tion in these patients. Furthermore, in human autoim-
mune diseases, elevated levels of serum BAFF may con-
tribute to the disease not only by breaking tolerance
during B cell development (24), but by enhancing sur-
vival of plasmablasts in the affected tissues as well.
During differentiation of memory B cells to CD38+
effector cells, expression of some surface receptors
altered. Strikingly, CD40 and BAFF-R were downregu-
lated, while BCMA was induced. Downregulation of
CD40 on CD38+ ISCs is consistent with previous stud-
ies demonstrating reduced expression of CD40 on plas-
ma cells compared with mature B cells (51). Similarly,
the reduced expression of BAFF-R on CD38+ ISCs
resembled the loss of expression of BAFF-R from pri-
mary human CD38++CD20+/– ISCs (data not shown).
Our observation that BCMA was weakly expressed on
in vitro–derived CD38+ plasmablasts is consistent with
earlier reports demonstrating BCMA to be absent or
only weakly expressed on pre-B and mature B cell lines,
yet present at highest levels on myeloma cell lines (31).
Importantly, our data confirm recent studies demon-
strating CD38+ plasmablasts generated in vitro from
human memory B cells in a manner similar to our cul-
tures (52) express significantly higher levels of BCMA
than resting mature B cells. Thus, although BCMA was
originally reported to be localized intracellularly (31),
our data, together with gene expression studies (52)
and studies demonstrating that BCMA can be weakly
expressed on the surface of tonsil B cells (13) and sta-
bly transfected 293T cells (13, 28), suggest BCMA can
indeed be expressed as a transmembrane receptor. The
reduction in the level of CD40 on in vitro–generated
CD38+ B cells provides an explanation for the loss of
dependence on CD40L for the continued growth and
survival of these cells (36). This loss of CD40L depend-
ency may be compensated by the acquisition of BCMA
through which BAFF could elicit downstream signal-
ing pathways independently of BAFF-R (23, 25, 28, 29).
Moreover, experiments investigating the effect of the
BAFF homologue APRIL lent additional support for a
role for BCMA, rather than BAFF-R, in maintaining
survival of CD38+ ISCs. The observation that popula-
tion 2 expresses higher levels of BAFF-R than popula-
tion 3, yet is only minimally affected by BAFF, is further
evidence that BCMA may mediate BAFF signaling on
CD38+ B cells. The possibility, however, that APRIL
may exert its effect through a non-BAFF binding–spe-
cific receptor cannot be excluded (24). Taken together,
these findings point to the possible occurrence of a
developmental switch during B cell differentiation
whereby BAFF exerts its antiapoptotic effect through
distinct counter-receptors.
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Table 1
Effect of BAFF on Ig secretion by primary plasma cells
Ig secretion (ng/ml)
% Ki67+ Ig isotype –BAFF +BAFF
Experiment 1 IgM 125.0 298.3
(spleen PB) >90% IgG 39.9 85.1
IgA 126.3 212.2
Experiment 2 IgM 560.0 528.8
(spleen PC) <1% IgG 25.3 9.7
IgA 168.7 120.0
Experiment 3 IgM 15.7 13.2
(BM PC) <1% IgG 179.8 227.0
IgA 37.1 32.2
CD38++CD20+/– cells (5× 103 to 10 × 103) from human spleens (experiments
1 and 2) or BM (experiment 3) were isolated by cell sorting and were cultured
for 4–5 days in media containing IL-2/IL-10 in the absence or presence of sol-
uble BAFF. The proportion of cells expressing Ki67 was determined prior to
culture. Levels of secreted IgM, IgG, and IgA were determined by Ig heavy
chain–specific immunoassays. Each value represents the mean of duplicate
cultures. PB, plasmablast; PC, plasma cell.
Our data suggest that a more detailed analysis of
BCMA-deficient mice may reveal a function for this
receptor in the effector phase of a humoral immune
response. It has been clearly demonstrated that BCMA
is dispensable for B cell development (14, 15, 32),
because BAFF-R is the predominant receptor that deliv-
ers survival signals to B cells during ontogeny. None of
these studies, however, examined the development of
ISCs or plasma cells in BCMA-deficient mice (14, 15,
32). The one study that did examine a T cell–depend-
ent immune response measured the levels of Ag-specif-
ic serum IgG1 and found the levels in BCMA–/– mice
did not differ significantly from wild-type controls
(32). This is perhaps not surprising because the serum
level of IgG1 is least affected in BAFF transgenic mice
(less than twofold increase). On the other hand, IgA
was increased more than 100-fold (17). Taken with our
data demonstrating BAFF resulted in increased levels
of IgA but not IgG, it is possible that an immune defect
against an Ag that induces an IgA response may be
affected in BCMA-deficient mice. Alternatively, because
the affinity of interaction between BAFF and human
BCMA is much greater than that between BAFF and
mouse BCMA (15), this receptor may have a distinct
function in human B cell differentiation compared
with the murine system.
When the effect of BAFF on primary CD38++CD20+/–
B cells was examined, it was found to increase the level
of Ig secreted in vitro by plasmablasts but not plasma
cells. Thus, BAFF may preferentially contribute to the
survival of plasmablasts generated in secondary lym-
phoid tissues as opposed to terminally differentiated
plasma cells. This is reminiscent of a recent study
demonstrating the important contribution of BAFF to
the survival and subsequent persistence of Ag-specific
plasmablasts generated from marginal zone B cells
within the murine spleen (46), again highlighting the
similarities between data obtained from our in vitro cul-
ture system and in vivo models of B cell differentiation.
Because human memory B cells localize to the splenic
marginal zone (37, 53), a similar mechanism may pro-
mote the viability of ISCs rapidly generated from
human marginal zone/memory B cells following
encounters with blood-borne antigens. As plasmablasts
undergo further maturation and migration from lym-
phoid areas to red pulp of spleen and BM, factors such
as cytokines and stromal cells located in these areas (54)
may substitute for BAFF as a source of survival signals.
BAFF is secreted by monocytes, macrophages, and
DCs, and the amount produced is increased by CD40L
or IL-10 (46, 48, 55, 56), both of which are required for
the generation of CD38+ B cells from human memory B
cells in vitro (36). In vivo, DCs and CD40L-expressing
CD4+ memory T cells localize to the outer zone of ger-
minal centers (57, 58), where high-affinity Ag-specific B
cells undergo selection and differentiation into memo-
ry cells or plasma cells (2). Thus, BAFF and IL-10 pro-
duced by DCs following interaction with CD40L+ T cells
may act in concert to facilitate survival and expansion
of Ag-specific plasmablasts. The production of IL-10 in
such a microenvironment may not only facilitate the
generation of CD38+ B cells from memory B cells (36),
but also increase the concentration of secreted BAFF
(55, 56), resulting in increased persistence of CD38+
ISCs. Moreover, it has recently been reported that BAFF
can induce IL-10 secretion by a human B cell line (59),
suggesting an additional mechanism whereby BAFF
may promote survival of activated human B cells in the
presence of autocrine IL-10.
Our data have shed light on a possible mechanism
for the development, as well as treatment, of some
human autoimmune diseases. Patients with SLE
exhibit elevated serum levels not only of BAFF (19–21),
but also IL-10 aberrantly produced by B cells and
monocytes (60). Because IL-10 has been found to be a
potent inducer of BAFF production by human
myeloid cells (55, 56), it is possible that elevated levels
of serum BAFF in SLE are secondary to the elevated
levels of serum IL-10 in these patients. Thus, the com-
bined effect of BAFF and IL-10 on the survival of ISCs
in vitro may be recapitulated in vivo in the pathogen-
esis of some B cell–mediated autoimmune diseases.
Consequently, targeting IL-10 (60) in addition to
BAFF may have therapeutic benefit for the outcome of
SLE, rheumatoid arthritis, and Sjögren’s syndrome. In
conclusion, our results describing BAFF as a novel sur-
vival factor for human differentiated ISCs have wide-
ranging implications for the treatment of human
immunodeficiencies as well as autoimmune diseases.
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